Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) EVP Zachary Roberts sold 27,199 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total transaction of $48,414.22. Following the transaction, the executive vice president now owns 488,054 shares of the company’s stock, valued at $868,736.12. This trade represents a 5.28 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Allogene Therapeutics Stock Up 3.2 %
ALLO opened at $1.94 on Friday. Allogene Therapeutics, Inc. has a 52 week low of $1.78 and a 52 week high of $5.78. The business’s 50 day moving average is $2.12 and its two-hundred day moving average is $2.51. The firm has a market cap of $406.76 million, a price-to-earnings ratio of -1.24 and a beta of 0.86.
Hedge Funds Weigh In On Allogene Therapeutics
A number of institutional investors have recently modified their holdings of the business. Geode Capital Management LLC increased its stake in Allogene Therapeutics by 14.4% in the third quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock valued at $9,037,000 after purchasing an additional 407,070 shares during the period. Perceptive Advisors LLC purchased a new stake in Allogene Therapeutics during the 2nd quarter valued at approximately $6,349,000. Dimensional Fund Advisors LP lifted its position in Allogene Therapeutics by 24.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock worth $5,944,000 after acquiring an additional 507,021 shares during the period. Lynx1 Capital Management LP purchased a new position in shares of Allogene Therapeutics in the 2nd quarter valued at approximately $5,192,000. Finally, Renaissance Technologies LLC raised its stake in shares of Allogene Therapeutics by 340.4% during the second quarter. Renaissance Technologies LLC now owns 1,747,955 shares of the company’s stock worth $4,073,000 after purchasing an additional 1,351,055 shares during the last quarter. 83.63% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Get Our Latest Stock Report on Allogene Therapeutics
About Allogene Therapeutics
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).
Read More
- Five stocks we like better than Allogene Therapeutics
- Health Care Stocks Explained: Why You Might Want to Invest
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- Insider Buying Explained: What Investors Need to Know
- 3 Buy-and-Hold Stocks for Long-Term Growth
- What Are Dividend Contenders? Investing in Dividend Contenders
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.